Malouf et al. reported an objective response rate of 33.0% for an mTOR inhibitor in patients with metastatic Xp11.2 tRCC [22]. Here, MTOR is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.